Disease

EQS-News: ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease

Retrieved on: 
Wednesday, April 10, 2024
Cell, Bone marrow, Disease, Transplant, Risk, Clinic, Patient, Gastrointestinal tract, Mortality, Haematopoietic system, Leukemia, Quality of life, Graft-versus-host disease, Clinical trial, Skin, Safety, CSO, Liver, Acute leukemia, Vaccine

GvHD is a severe and potentially life-threatening complication that can arise after an allogeneic haematopoietic stem cell transplantation and affects about 50 % of recipients.

Key Points: 
  • GvHD is a severe and potentially life-threatening complication that can arise after an allogeneic haematopoietic stem cell transplantation and affects about 50 % of recipients.
  • GvHD occurs when the stem cell donor’s T cells attack the patient’s tissues, leading to a range of symptoms that can affect the skin, gastrointestinal tract, and liver.
  • Prof. Dr. Andrea Tüttenberg, CEO of ActiTrexx, said: “GvHD can lead to life-long symptoms for the patient and is a major cause for the high mortality rate of blood stem cell transplantation.
  • Ten patients who have recently received a blood stem cell transplantation as treatment for leukemia will receive a single treatment with Actileucel.

EQS-News: Bayer and Aignostics to collaborate on next generation precision oncology

Retrieved on: 
Wednesday, April 10, 2024
Algorithm, Disease, Drug discovery, Intelligence, Partnership, Patient, Hospital, Artificial intelligence, Cancer, Executive Committee, AI, Biology, Bayer, Pathology, Machine learning, Pharmaceutical industry

Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.

Key Points: 
  • Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.
  • The partners will co-create a novel target identification platform that leverages Aignostics’ technology and proprietary multimodal patient cohorts, and Bayer’s deep expertise in discovering and developing novel oncology therapies.
  • Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare,” said Viktor Matyas, CEO of Aignostics GmbH.
  • Aignostics will receive an upfront payment and is eligible to receive success-based milestone payments and royalties on any commercialized therapies that result from the collaboration.

Global Experts from SEPA Call for the Control of Gingivitis Rather than Waiting for Periodontitis to Develop

Retrieved on: 
Monday, April 8, 2024
CASA, Toothpaste, Head, Confusion, Tooth brushing, EFP, Journal of Clinical Periodontology, Patient, Quality of life, Complutense University of Madrid, UCM, Therapy, Dental, Oral hygiene, Etiology, United States of Europe, Risk, Education, Gingivitis, Treatment, Recurrence, Dentistry, Prevalence, Disease, Clinical, White paper, Public, Knowledge, Research, University, Overalls, University College London, Mouthwash, Dentist, Molina Healthcare, Health, Motivation, Incidence, Physician, British Dental Journal, Inflammation, Pharmacist, Plaque, Systematic review, Bleeding, S3, Meta-analysis

SEPA: Limited knowledge among oral health teams of the recommendations and evidence currently available on oral antiseptics (that are clinically proven to be effective) reduces their implementation; therefore, more practical and simple advice is proposed.

Key Points: 
  • This was highlighted at an International Summit of Experts held at the Casa de las Encías in Madrid, Spain, the headquarters of the SEPA Foundation.
  • "Periodontal diseases are prevalent worldwide, affecting hundreds of millions of people," says the meeting coordinator, Dr. Paula Matesanz, vice president of SEPA.
  • As Dr. Iain Chapple summarizes, "It is time for a paradigm shift: we must control gingivitis and not wait until periodontitis develops."
  • J Clin Periodontol 2022 Jun:49 Suppl 24:4-71 (version adapted by SEPA available at https://portal.guiasalud.es/gpc/tratamiento-periodontitis-estadio-iv )
    * Chapple I, Time to take gum disease seriously.

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Retrieved on: 
Tuesday, April 2, 2024
Hypertrophy, Heart, CRDL, Patient, Mayo Clinic, PPAR, Agent handling, Cleveland Clinic, Fibrosis, European, Therapy, Myocarditis, Analysis, American Heart Association, Human, Massachusetts General Hospital, Pericarditis, MMT, Heart failure, American College, Safety, ODD, Cardiology, Clinical professor, Disease, Pericardium, Research, World Heart Federation, Management, University, Death, Pericardial effusion, Maverick, Reactive oxygen species, TSX, Priority review, FDA, Conversation, Financial statement, Inflammation, Fast Track, Calcium, Wound healing, API, Pharmaceutical industry

"Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.

Key Points: 
  • "Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.
  • In January 2023, Cardiol announced the first patient had been enrolled in the Company's Phase II open-label pilot study ("MAvERIC-Pilot") investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis.
  • In November 2023, Cardiol announced that it had exceeded 50% of the patient enrollment target for the MAvERIC-Pilot study.
  • In January 2024, Cardiol announced that ARCHER had exceeded 50% patient enrollment and was progressing ahead of the original study timeline.

Luventix to Present at The LD Micro Invitational XIV

Retrieved on: 
Thursday, March 21, 2024
Artificial intelligence, Sofitel New York Hotel, Probability, Disease

Henderson, Nevada--(Newsfile Corp. - March 21, 2024) - Luventix Inc., a development-stage company pioneering Intelligent Disease Diagnostics using Artificial Intelligence to determine the probability that a person has a disease, announced today that it will be presenting at the 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024.

Key Points: 
  • Henderson, Nevada--(Newsfile Corp. - March 21, 2024) - Luventix Inc., a development-stage company pioneering Intelligent Disease Diagnostics using Artificial Intelligence to determine the probability that a person has a disease, announced today that it will be presenting at the 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024.
  • The event is expected to feature 80 companies presenting in half-hour increments, as well as private 1:1 meetings.
  • Luventix is scheduled to present on April 9th, at 4pm.
  • George B. Holmes, Co-Founder & CEO will be leading the presentation.

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Retrieved on: 
Tuesday, April 9, 2024
ITK, Atopic dermatitis, Patient, Disease, Cytokine

BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of the Company’s randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial is expected to enroll 64 patients at 12 sites in the United States, with the potential for initial clinical data before year-end 2024.

Key Points: 
  • Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor
    BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of the Company’s randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
  • The trial is expected to enroll 64 patients at 12 sites in the United States, with the potential for initial clinical data before year-end 2024.
  • “The initiation of our Phase 1 atopic dermatitis trial is an important step towards unlocking the broad potential of ITK inhibition for immune diseases,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus.
  • In addition, the Company has evaluated soquelitinib in companion dogs with naturally occurring, refractory atopic dermatitis.

American Kidney Fund and Alonzo Mourning Call for More Awareness and Understanding of APOL1-Mediated Kidney Disease (AMKD) on Capitol Hill

Retrieved on: 
Tuesday, April 9, 2024
American Kidney Fund, African Americans, Health, Apolipoprotein L1, L1, APOL1, Genetic testing, Disease, Risk, Policy, Black, Kidney disease, Vertex Pharmaceuticals, AKF, Pharmaceutical industry

ROCKVILLE, Md., April 09, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and basketball Hall-of-Famer Alonzo Mourning are teaming up on Capitol Hill for a roundtable and policy discussion to highlight the stories of people with APOL1-mediated kidney disease (AMKD) and spread awareness of this rapidly progressive form of genetic kidney disease.

Key Points: 
  • ROCKVILLE, Md., April 09, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and basketball Hall-of-Famer Alonzo Mourning are teaming up on Capitol Hill for a roundtable and policy discussion to highlight the stories of people with APOL1-mediated kidney disease (AMKD) and spread awareness of this rapidly progressive form of genetic kidney disease.
  • The roundtable is being held in conjunction with the nation’s first ever AMKD Awareness Day , which AKF is launching on April 30, 2024.
  • “For many years, I have publicly shared my personal kidney disease story to help educate people about APOL1-mediated kidney disease,” said Mourning.
  • Also participating in the roundtable discussion are:
    Support for AMKD Awareness Day activities, including this roundtable discussion, is provided by Vertex Pharmaceuticals Incorporated.

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Retrieved on: 
Tuesday, April 9, 2024
CPI, CPS, Disease, HNSCC, Patient, SAN, Inflammation, Pembrolizumab, HPV, AACR, CCR4, Therapy, PD-L1, Safety, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) --  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced). The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

Key Points: 
  • The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
  • The AACR poster highlighted data from the 32-patient CPI-experienced HNSCC cohort in the trial evaluating tivumecirnon, an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with pembrolizumab.
  • Patients in this cohort had heavily pretreated disease, with 69% of patients having received three or more (up to six) prior lines of treatment.
  • In the entire cohort, confirmed responses were observed in 5/32 patients (15.6%) regardless of PD-L1 or HPV status.

Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation

Retrieved on: 
Tuesday, April 9, 2024
Blood pressure, Ethanol, Collateral damage, Disease, Nervous system, Patient, Renal artery, Pain, AMIX, Hypertension, Pharmaceutical industry

THE WOODLANDS, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the successful completion of an animal study evaluating the Company’s proprietary catheter-based sensing technology for use in the renal artery.

Key Points: 
  • The preclinical porcine model study was designed to assess the ability of the Company’s catheter-based sensing technology to effectively sense and target individual nerves surrounding the renal artery.
  • These results strongly demonstrate the potential of Autonomix’s sensing technology to successfully locate nerves around the renal artery.
  • These nerves include those responsible for regulating blood pressure and are the target of recently approved renal denervation procedures for hypertension.
  • The successful completion of this preclinical study provides us with confidence in the potential of our sensing technology to ultimately make renal denervation safer, faster, and more effective.

Emerging Markets Report: Follow the Leader

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Disease, Biomedical Research, Patient, HPC, Health care, Artificial intelligence, NVDA, AI, WELL, A.I, TSX, Inflammatory bowel disease, Love, NVIDIA, Map, AIDX, Medicine, Medical device

ORLANDO, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- For some time now the market has been in love with Nvidia (NVDA), the behemoth stock which has been to say the least, a bell cow for the market. And while we don’t discuss actual share prices in our pages, preferring to focus instead on the items that historically drive favorable valuations, Nvidia’s price appreciation has been remarkable and is, powered by their revenue growth and the public’s attraction to Artificial Intelligence technology.

Key Points: 
  • And we believe that the intersection of Health Care and Artificial Intelligence is the first half of that formula.
  • With NVIDIA, healthcare institutions can harness the power of AI and high-performance computing (HPC) to define the future of medicine.
  • If the revenue trend continues, analysts, partners, and market interests may follow.
  • And HEALWELL is certainly following the leader, acquiring and developing potentially lucrative Healthcare A.I.